Tags

Type your tag names separated by a space and hit enter

[Macrophage-colony stimulating factor and ovarian cancer].
Minerva Ginecol. 1999 Jul-Aug; 51(7-8):261-4.MG

Abstract

BACKGROUND

In this study the use of macrophage-colony stimulating factor (M-CSF) as tumor marker for ovarian cancer is evaluated.

METHODS

Serum samples were obtained from 74 patients, 43 of these were affected by ovarian carcinoma and 31 by benign ovarian tumors. The M-CSF levels were assayed with an ELISA method and compared with those of 148 healthy women. CA 125 levels were also evaluated.

RESULTS

In healthy women the M-CSF levels were 770.4 +/- 145.9 U/ml, the upper limit of normal level was considered 1056 U/ml. Serum M-CSF levels were significantly high in patients with ovarian cancer (1425.3 +/- 1007.1 U/ml; p < 0.001) and in 29 of the 43 patients exceeded the limit of 1056 U/ml. No differences were observed among the histologic types. There were no significant differences between patients with benign ovarian pathology and healthy women. No definite relationship was found with CA 125, but evaluating at the same time M-CSF and CA 125 positive results were found in 95.3% of cases.

CONCLUSIONS

Therefore M-CSF can be considered a marker for ovarian cancer, and the assay of its serum levels can be particularly useful in association with those of CA 125.

Authors+Show Affiliations

Istituto di Clinica Ostetrica e Ginecologica, Seconda Università degli Studi, Napoli.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ita

PubMed ID

10536419

Citation

Menditto, A, et al. "[Macrophage-colony Stimulating Factor and Ovarian Cancer]." Minerva Ginecologica, vol. 51, no. 7-8, 1999, pp. 261-4.
Menditto A, Piscittelli V, Cassese F, et al. [Macrophage-colony stimulating factor and ovarian cancer]. Minerva Ginecol. 1999;51(7-8):261-4.
Menditto, A., Piscittelli, V., Cassese, F., Balbi, G. C., Balbi, C., & Cardone, A. (1999). [Macrophage-colony stimulating factor and ovarian cancer]. Minerva Ginecologica, 51(7-8), 261-4.
Menditto A, et al. [Macrophage-colony Stimulating Factor and Ovarian Cancer]. Minerva Ginecol. 1999 Jul-Aug;51(7-8):261-4. PubMed PMID: 10536419.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Macrophage-colony stimulating factor and ovarian cancer]. AU - Menditto,A, AU - Piscittelli,V, AU - Cassese,F, AU - Balbi,G C, AU - Balbi,C, AU - Cardone,A, PY - 1999/10/28/pubmed PY - 1999/10/28/medline PY - 1999/10/28/entrez SP - 261 EP - 4 JF - Minerva ginecologica JO - Minerva Ginecol VL - 51 IS - 7-8 N2 - BACKGROUND: In this study the use of macrophage-colony stimulating factor (M-CSF) as tumor marker for ovarian cancer is evaluated. METHODS: Serum samples were obtained from 74 patients, 43 of these were affected by ovarian carcinoma and 31 by benign ovarian tumors. The M-CSF levels were assayed with an ELISA method and compared with those of 148 healthy women. CA 125 levels were also evaluated. RESULTS: In healthy women the M-CSF levels were 770.4 +/- 145.9 U/ml, the upper limit of normal level was considered 1056 U/ml. Serum M-CSF levels were significantly high in patients with ovarian cancer (1425.3 +/- 1007.1 U/ml; p < 0.001) and in 29 of the 43 patients exceeded the limit of 1056 U/ml. No differences were observed among the histologic types. There were no significant differences between patients with benign ovarian pathology and healthy women. No definite relationship was found with CA 125, but evaluating at the same time M-CSF and CA 125 positive results were found in 95.3% of cases. CONCLUSIONS: Therefore M-CSF can be considered a marker for ovarian cancer, and the assay of its serum levels can be particularly useful in association with those of CA 125. SN - 0026-4784 UR - https://www.unboundmedicine.com/medline/citation/10536419/[Macrophage_colony_stimulating_factor_and_ovarian_cancer]_ L2 - http://www.diseaseinfosearch.org/result/5504 DB - PRIME DP - Unbound Medicine ER -